Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single‐institution, modern cohort study
- 16 July 2021
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 43 (11) , 3331-3344
Abstract
Background: Recurrent head and neck cancer has poor prognosis. Stereotactic body radiotherapy (SBRT) may improve outcomes by delivering ablative radiation doses.Methods: We reviewed patients who received definitive‐intent SBRT reirradiation at our institution from 2013 to 2020. Patterns of failure, overall survival (OS), and toxicities were analyzed.Results: One hundred and thirty‐seven patients were evaluated. The median OS was 44.3 months. The median SBRT dose was 45 Gy and median target volume 16.9 cc. The 1‐year local, regional, and distant control was 78%, 66%, and 83%, respectively. Systemic therapy improved regional (p = 0.004) and distant control (p = 0.04) in nonmetastatic patients. Grade 3+ toxicities were more common at mucosal sites (p = 0.001) and with concurrent systemic therapy (p = 0.02).Conclusions: In a large cohort of SBRT reirradiation for recurrent, small volume head and neck cancers, a median OS of 44.3 months was observed. Systemic therapy improved regional and distant control. Toxicities were modulated by anatomic site and systemic therapy.Keywords
Funding Information
- National Institute of Dental and Craniofacial Research (R01DE027445)
- National Science Foundation (NSF 1933369)
- National Institutes of Health (P30CA016672)
- National Cancer Institute (1R01CA218148)
- National Institute of Dental and Craniofacial Research (R01DE028290)
- National Institutes of Health (R25EB025787‐01)
This publication has 47 references indexed in Scilit:
- Salvage Reirradiaton With Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic body radiation therapy: The report of AAPM Task Group 101Medical Physics, 2010
- Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapyActa Oncologica, 2010
- Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Fractionated Stereotactic Radiotherapy as Reirradiation for Locally Recurrent Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck RegionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911Journal of Clinical Oncology, 2007
- Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neckHead & Neck, 2007